- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04798508
EXPRE-SON-REA : Expressive Own Names in Neurophysiologic Assessment of Comatose Patients (EXPRESONREA)
EXPRE-SON-REA : Expressive Versus Neutral Own Names in Neurophysiologic Prognosis Assessment of Intensive Care Unit Comatose Patients.
Evaluating the neurologic prognosis in disorders of consciousness (DOC) patients is still a crucial issue in intensive care units.
Neurophysiology allows the investigators to record cerebral responses of patients to auditory stimuli and in particularly to their own name. Numerous studies try to improve the relevance of the auditory stimuli used in this paradigm.
Here the investigators assess if the use of own name stimuli uttered by more expressive voices (for example smiling voices) modulates the cerebral responses recorded. They then correlate these cerebral responses to the neurologic prognosis at three months.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Late auditory evoked potentials (as P3 wave) are used in neurophysiology to assess the level of consciousness in DOC (disorder of consciousness) patients. The P3 wave, elicited by listening standard and deviant stimuli, corresponds to the activation of a frontoparietal network and is considered to reflect a cognitive attention task. Using the own name of the patient as deviant stimuli improve the ability to detect the P3 wave because of the particularly relevance of this stimulus for the patient. However the correlation of this P3 wave and neurologic prognosis is still imperfect and depends on the etiology of the DOC.
In human cognition, to identify the expressivity valence of a voice is essential. Neural processing of expressive voices involves more widespread brain areas than neutral voices processing.
Here the investigators assume that using own name stimuli uttered by more expressive voices (positive : smiling voice or negative : rough voice) should recruit more widespread brain areas and modulate the cerebral responses recorded. The investigators then evaluate if these cerebral responses are relevant markers of consciousness and correlate them to neurologic prognosis at three months.
Opintotyyppi
Ilmoittautuminen (Odotettu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Estelle Pruvost-Robieux, MD
- Puhelinnumero: + 33 1 45 65 81 89
- Sähköposti: e.pruvost@ghu-paris.fr
Tutki yhteystietojen varmuuskopiointi
- Nimi: Martine Gavaret, Professor
- Puhelinnumero: + 33 1 45 65 81 89
- Sähköposti: m.gavaret@ghu-paris.fr
Opiskelupaikat
-
-
-
Paris, Ranska, 75014
- Rekrytointi
- GHU Paris Psychiatrie Neurosciences
-
Ottaa yhteyttä:
- Estelle Pruvost-Robieux, MD
- Puhelinnumero: +33 1 45 65 81 89
- Sähköposti: e.pruvost@ghu-paris.fr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age over 18
- Disorder of consciousness defined as :
Glasgow coma scale < 8 or >8 but
- eyes opening to pain only
- No response to basic command
- Available neuro-imagery (CT-scan or MRI)
- Normal temperature (no fever or hypothermia)
- Normal blood pressure during neurophysiologic evaluation
- Given consent from relatives
Exclusion Criteria:
- Brain death
- Known deafness
- Severe sepsis uncontrolled during neurophysiologic evaluation
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Ei käytössä
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Muut: Whole group
The whole group listen successively the 3 paradigms :
|
Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Positive predictive values of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices for the neuroprognosis at 3 months
Aikaikkuna: 3 months from DOC evaluation
|
Determination of the positive predictive values of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
|
Negative predictive values of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
Aikaikkuna: 3 months from DOC evaluation
|
Determination of the negative predictive values of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
|
Sensitivity of P3a responses occurences to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
Aikaikkuna: 3 months from DOC evaluation
|
Determination of the sensibility of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
|
Specificity of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
Aikaikkuna: 3 months from DOC evaluation
|
Determination of the specificity of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Negative predictive value of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
Aikaikkuna: 7, 14 and 28 days from DOC evaluation
|
Determination of the negative predictive value of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Positive predictive value of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
Aikaikkuna: 7, 14 and 28 days from DOC evaluation
|
Determination of the positive predictive value of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Sensitivity of P3a responses occurences uttered by expressive voices and neutral voices according to the CRS-r scale
Aikaikkuna: 7, 14 and 28 days from DOC evaluation
|
Determination of the sensibility of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Specificity of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
Aikaikkuna: 7, 14 and 28 days from DOC evaluation
|
Determination of the specificity of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Negative predictive value of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
Aikaikkuna: 3 months
|
Determination of the negative predictive value of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Positive predictive value of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
Aikaikkuna: 3 months
|
Determination of the positive predictive value of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Sensitivity of P3a responses occurences uttered by expressive voices and neutral voices according to eyes-opening
Aikaikkuna: 3 months
|
Determination of the sensibility of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Specificity of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
Aikaikkuna: 3 months
|
Determination of the specificity of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Description of the amplitudes of the P3a wave to own-name uttered by expressive voices versus neutral voices.
Aikaikkuna: 3 months
|
Amplitudes of P3a waves recorded with own name uttered by expressive and neutral voices
|
3 months
|
|
Description of the latencies of the P3a wave to own-name uttered by expressive voices versus neutral voices.
Aikaikkuna: 3 months
|
Latencies of P3a waves recorded with own name uttered by expressive and neutral voices
|
3 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Odotettu)
Opintojen valmistuminen (Odotettu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 2020-A00747-32
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Evoked related potential - P3 paradigm
-
Stanford UniversityRekrytointiKrooninen lantion kivun oireyhtymäYhdysvallat
-
University of Wisconsin, MadisonMeriter FoundationRekrytointiHypoksi-iskeeminen enkefalopatia | Vastasyntyneen enkefalopatia | EnkefalopatiaYhdysvallat
-
Brugmann University HospitalRekrytointiMultippeliskleroosiBelgia